Pathogenesis of human cytomegalovirus in the immunocompromised host

Human cytomegalovirus (HCMV) infection is ordinarily controlled by a vigorous immune response; however, HCMV can replicate to high levels and cause end organ disease when the immune system is compromised. In this Review, Griffiths and Reeves discuss HCMV pathogenesis in immunocompromised individuals and emerging strategies to treat and prevent infection and disease. Human cytomegalovirus (HCMV) is a herpesvirus that infects similar to 60% of adults in developed countries and more than 90% in developing countries. Usually, it is controlled by a vigorous immune response so that infections are asymptomatic or symptoms are mild. However, if the immune system is compromised, HCMV can replicate to high levels and cause serious end organ disease. Substantial progress is being made in understanding the natural history and pathogenesis of HCMV infection and disease in the immunocompromised host. Serial measures of viral load defined the dynamics of HCMV replication and are now used routinely to allow intervention with antiviral drugs in individual patients. They are also used as pharmacodynamic read-outs to evaluate prototype vaccines that may protect against HCMV replication and to define immune correlates of this protection. This novel information is informing the design of randomized controlled trials of new antiviral drugs and vaccines currently under evaluation. In this Review, we discuss immune responses to HCMV and countermeasures deployed by the virus, the establishment of latency and reactivation from it, exogenous reinfection with additional strains, pathogenesis, development of end organ disease, indirect effects of infection, immune correlates of control of replication, current treatment strategies and the evaluation of novel vaccine candidates.